Oncology Development Articles & Analysis: Older
5 articles found
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. The pioneering ...
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. This means that approximately $60 billion dollars are spent annually on unsuccessful drugs.1,2 Contributing to these unchecked costs ...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. Small molecule drugs ...
Ongoing research and inventions in the field of oncology focus on the development of small molecule drug therapies for use in brain tumor resection. Small molecule drugs are being developed to target and effectively treat brain tumors to improve therapeutic outcomes. Small particles containing compounds that can enter cells and interact with specific targets to inhibit or modulate their ...
Navigating Cancer announced today that Alexandra Snyder, MD, Chief Medical Officer at Generate Biomedicines, has agreed to join its board of directors. Dr. Snyder is succeeding David M. Rubin, Ph.D. who served on Navigating Cancer’s Board from 2015 to the present. “We are pleased to welcome Dr. Snyder to Navigating Cancer’s Board and especially value her point of view as a ...